Don't want ads? Subscribe or login now.

Cancer Biotech, 2 Others Score IPOs Totaling $279M

By Matthew Guarnaccia · April 17, 2019, 7:13 PM EDT

Cancer-focused biotechnology firm Turning Point Therapeutics made its public debut Wednesday, recording the most lucrative initial public offering of three companies that brought in a combined $279 million....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Recent Articles By Matthew

July 25, 2019
5 Cos. Hit The Market With Combined $879M In IPOs
July 19, 2019
3 Cos. Raise $1B In IPOs Led By Peruvian Asset Manager
July 17, 2019
US Bank Escapes Most Of Trust Insurer's Settlement Suit
July 16, 2019
Insurer Off The Hook In Conn. Stadium Bond Fight
May 29, 2019
Concrete Co. Insurer Owes For Injury Settlement: 11th Circ.
May 24, 2019
8th Circ. Says Non-Matching Roof Tiles Not Insurer's Problem
April 03, 2019
Judge Adds Interest, Nixes Fees In Army Base Contract Fight
March 20, 2019
Insurance-Focused Blank Check Co. Scores $131M IPO
February 27, 2019
Israeli Energy Co. Delek Sells Insurer To PE Firms For $442M
January 09, 2019
Shutdown May Slow CVS-Aetna Deal Review, DOJ Says

Cancer Biotech, 2 Others Score IPOs Totaling $279M

Related Sections

Recent Articles By Matthew